Page 7 - நிறுவனம் கணக்குவைப்பு முறை ஓவர்‌ஸைட் பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Saniona AB: Saniona publishes its year-end report for 2020 Revenue was SEK 8.2 M (7.2 M) Operating loss was SEK -159.4 (-93.6 M) Net loss was SEK -73.4 M (-68.8 M) Earnings per share were SEK -1.79 (-2.67) Diluted earnings per share were SEK -1.75 (-2.67) Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M) Operating loss was SEK -68.8 M (-28.2 M) Net loss was SEK -45.6 M (-6.8 M) Earnings per share were SEK -0.73 (-0.24) Diluted earnings per share were SEK -0.73 (-0.24) Business highlights in Q4 2020 Saniona achieved positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a double-blind trial followed by a 24-week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. Tesomet was well tolerated, and no clinically meaningful differe

United statesUnited kingdomTrista morrisonUniversity of pennsylvaniaBoehringer ingelheimDrug administrationTreatment research centerUs public company accounting oversight boardInvestigational new drugDenelle waynickChief legal officerKyle haraldsenChief technical operationsCadent therapeuticsRisk evaluationMitigation strategy